Breast Cancer

Isoflavone supplements may influence outcomes among patients with breast cancer.

Most models were cancer-free within 6 weeks of treatment with selenomab-drug conjugates.

Next-generation antibody treatments effectively deliver cytotoxic drugs to tumors.

Top news of the week in oncology and cancer drug development.

The addition of abemaciclib to fulvestrant appeared to effectively improve progression-free survival in patients with breast cancer.

The addition of abemaciclib to fulvestrant appeared to effectively improve progression-free survival.

New research indicates that high consumption of certain dairy products may either increase or decrease the risk of developing breast cancer, depending on the food.

High yogurt intake may protect against breast cancer, while processed cheeses may increase cancer risk.

Eli Lilly and Company recently announced positive late-stage results in its clinical trial testing a combination of its experimental breast cancer drug and another widely-used treatment.

The risk of a second cancer remained high even 30 years after treatment.

Progression-free survival with IMMU-132 increases from an average of 3.5 months to 16.6 months in patients with breast cancer.

Mylan gains global licenses for its biosimilar to trastuzumab (Herceptin).

Improvements in breast cancer patient quality of life and mortality seen over last 30 years.

Scientists discover a metabolic weakness in advanced breast cancer cells.

Adding pertuzumab (Perjeta) to a breast cancer treatment regimen reduced recurrent disease.

Ribociclib plus letrozole shows improved survival in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2) advanced or metastatic breast cancer.

Ribociclib plus letrozole improved progression free survival in patients with HR+/HER2 advanced or metastatic breast cancer.

The FDA has approved Novartis’ Kisqali (ribociclib), in combination with an aromatase inhibitor as initial endocrine-based therapy treatment, for the treatment of breast cancer.

Neoadjuvant chemotherapy decreased recurrence and increased survival in African American patients.

Compounds demonstrate high cancer-killing activity and low-toxicity in non-tumor cell line.

Targeted and individualized breast cancer treatment is viable.

Many patients with stage 1 and 2 breast cancer are administered aggressive chemotherapy.

Patients with early-stage breast cancer may not need aggressive treatment.

Updates on the national performance benchmarks for digital mammography.

Early-stage breast cancer patients with low muscle quality and quantity have twice the risk of hospitalization.